The absence of typical symptoms in early-stage lung cancer often leads to delayed diagnosis and progression to advanced disease, which carries a higher mortality rate. Early screening is therefore essential for timely detection. When prompted by a high index of suspicion—often due to key clinical signs—early diagnosis relies on a combination of blood tests, low-dose computed tomography (LDCT), and lung biopsy. Staging plays a crucial role in categorizing the disease, guiding the initiation of targeted treatment strategies.